



PONTIAK

Prevention Of NephroToxin Induced Acute Kidney Injury Trial

The Prevention of Nephrotoxin-Induced Acute Kidney Injury using Cilastatin (PONTIAK): A Phase 2B Vanguard Design, Randomized, Double-Blind, Placebo-Controlled Study



Janice MacKay, Research Manager, Nephrology Research Group, Cumming School of Medicine, University of Calgary


Dr. Matthew James MD PhD FRCP, PI, Professor Cumming School of Medicine, University of Calgary

Dr. Neesh Pannu MD SM FRCP, Co-PI, Professor Nephrology and Immunology, University of Alberta



ACT RFA 3 – Canadian Biotech/RCTs



Accelerating
Clinical Trials 
Accélérer les
Essais Cliniques



CIHR
IRSC

Canadian Institutes of
Health Research
Instituts de recherche
en santé du Canada


Evaluating Canadian Biotech with RCTs

- Arch Biopartners
- Cilastatin
- Nephrology – Acute Kidney Injury




Research Question

To evaluate whether the repurposed drug cilastatin is effective for prevention of Acute Kidney Injury (AKI) and downstream outcomes in hospitalized patients exposed to nephrotoxic medications




Design

The PONTIAK Study is a randomized, double blind, placebo-controlled superiority study in hospitalized adults at risk of nephrotoxic AKI



Timeline



Updates

- 1.0 FTE Clinical Research Coordinator
- Protocol and ICF completed
- REB application submitted
- SOP's, Monitoring plan, CRF's and Redcap data base under development
- Health Canada CTA in progress

